Cargando…
Impact of body mass on P2Y12-inhibitor de-escalation in acute coronary syndromes—a substudy of the TROPICAL-ACS trial
AIMS: Clinical guidelines recommend de-escalation antiplatelet strategies to reduce bleeding risk in acute coronary syndrome (ACS) patients, albeit with a weak recommendation. This substudy of the TROPICAL-ACS trial aimed to determine the impact of body mass on the efficacy of a platelet function te...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627813/ https://www.ncbi.nlm.nih.gov/pubmed/37015874 http://dx.doi.org/10.1093/ehjcvp/pvad027 |
_version_ | 1785131609098289152 |
---|---|
author | Komócsi, András Merkely, Béla Hadamitzky, Martin Massberg, Steffen Rizas, Konstantinos D Hein-Rothweiler, Ralph Gross, Lisa Trenk, Dietmar Sibbing, Dirk Aradi, Dániel |
author_facet | Komócsi, András Merkely, Béla Hadamitzky, Martin Massberg, Steffen Rizas, Konstantinos D Hein-Rothweiler, Ralph Gross, Lisa Trenk, Dietmar Sibbing, Dirk Aradi, Dániel |
author_sort | Komócsi, András |
collection | PubMed |
description | AIMS: Clinical guidelines recommend de-escalation antiplatelet strategies to reduce bleeding risk in acute coronary syndrome (ACS) patients, albeit with a weak recommendation. This substudy of the TROPICAL-ACS trial aimed to determine the impact of body mass on the efficacy of a platelet function testing-guided de-escalation regimen in ACS patients after percutaneous coronary intervention. METHODS AND RESULTS: Patients were randomized to prasugrel (control group) or a platelet function testing-guided regimen with clopidogrel or prasugrel defined after 1-week clopidogrel. The primary endpoint was the net clinical benefit [cardiovascular death, myocardial infarction, stroke, or Bleeding Academic Research Consortium (BARC) 2–5 bleeding] for 12 months. Overweight was defined as a body mass index >25 kg/m(2). Patients without overweight showed a significant net clinical benefit from the de-escalation strategy, while in overweight cases de-escalation was comparable to prasugrel treatment [hazard ratio (HR): 0.52; 95% confidence interval (CI): 0.31–0.88; P = 0.013 and HR: 0.95; 95% CI: 0.69–1.31, P = 0.717, P-non-inferiority = 0.03, respectively, P-interaction = 0.053]. The benefit of de-escalation in terms of the risk of bleeding or of the ischaemic events did not reach statistical significance. Bleeding events with de-escalation were less frequent in non-overweight patients but comparable in overweight patients (HR: 0.55; 95% CI: 0.30–1.03; P = 0.057 and HR: 0.95; 95% CI: 0.64–1.41, respectively, P-interaction = 0.147). Non-overweight patients had lower ischaemic event rates with de-escalation, while overweight cases had slightly less (HR: 0.47; 95% CI: 0.18–1.25; P = 0.128 and HR: 0.89; 95% CI: 0.53–1.50, respectively, P-interaction = 0.261). CONCLUSION: The strategy of guided dual antiplatelet therapy de-escalation was associated with a significant net clinical benefit in non-overweight patients, while the two strategies were equivalent in overweight patients. |
format | Online Article Text |
id | pubmed-10627813 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-106278132023-11-08 Impact of body mass on P2Y12-inhibitor de-escalation in acute coronary syndromes—a substudy of the TROPICAL-ACS trial Komócsi, András Merkely, Béla Hadamitzky, Martin Massberg, Steffen Rizas, Konstantinos D Hein-Rothweiler, Ralph Gross, Lisa Trenk, Dietmar Sibbing, Dirk Aradi, Dániel Eur Heart J Cardiovasc Pharmacother Original Article AIMS: Clinical guidelines recommend de-escalation antiplatelet strategies to reduce bleeding risk in acute coronary syndrome (ACS) patients, albeit with a weak recommendation. This substudy of the TROPICAL-ACS trial aimed to determine the impact of body mass on the efficacy of a platelet function testing-guided de-escalation regimen in ACS patients after percutaneous coronary intervention. METHODS AND RESULTS: Patients were randomized to prasugrel (control group) or a platelet function testing-guided regimen with clopidogrel or prasugrel defined after 1-week clopidogrel. The primary endpoint was the net clinical benefit [cardiovascular death, myocardial infarction, stroke, or Bleeding Academic Research Consortium (BARC) 2–5 bleeding] for 12 months. Overweight was defined as a body mass index >25 kg/m(2). Patients without overweight showed a significant net clinical benefit from the de-escalation strategy, while in overweight cases de-escalation was comparable to prasugrel treatment [hazard ratio (HR): 0.52; 95% confidence interval (CI): 0.31–0.88; P = 0.013 and HR: 0.95; 95% CI: 0.69–1.31, P = 0.717, P-non-inferiority = 0.03, respectively, P-interaction = 0.053]. The benefit of de-escalation in terms of the risk of bleeding or of the ischaemic events did not reach statistical significance. Bleeding events with de-escalation were less frequent in non-overweight patients but comparable in overweight patients (HR: 0.55; 95% CI: 0.30–1.03; P = 0.057 and HR: 0.95; 95% CI: 0.64–1.41, respectively, P-interaction = 0.147). Non-overweight patients had lower ischaemic event rates with de-escalation, while overweight cases had slightly less (HR: 0.47; 95% CI: 0.18–1.25; P = 0.128 and HR: 0.89; 95% CI: 0.53–1.50, respectively, P-interaction = 0.261). CONCLUSION: The strategy of guided dual antiplatelet therapy de-escalation was associated with a significant net clinical benefit in non-overweight patients, while the two strategies were equivalent in overweight patients. Oxford University Press 2023-04-04 /pmc/articles/PMC10627813/ /pubmed/37015874 http://dx.doi.org/10.1093/ehjcvp/pvad027 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Original Article Komócsi, András Merkely, Béla Hadamitzky, Martin Massberg, Steffen Rizas, Konstantinos D Hein-Rothweiler, Ralph Gross, Lisa Trenk, Dietmar Sibbing, Dirk Aradi, Dániel Impact of body mass on P2Y12-inhibitor de-escalation in acute coronary syndromes—a substudy of the TROPICAL-ACS trial |
title | Impact of body mass on P2Y12-inhibitor de-escalation in acute coronary syndromes—a substudy of the TROPICAL-ACS trial |
title_full | Impact of body mass on P2Y12-inhibitor de-escalation in acute coronary syndromes—a substudy of the TROPICAL-ACS trial |
title_fullStr | Impact of body mass on P2Y12-inhibitor de-escalation in acute coronary syndromes—a substudy of the TROPICAL-ACS trial |
title_full_unstemmed | Impact of body mass on P2Y12-inhibitor de-escalation in acute coronary syndromes—a substudy of the TROPICAL-ACS trial |
title_short | Impact of body mass on P2Y12-inhibitor de-escalation in acute coronary syndromes—a substudy of the TROPICAL-ACS trial |
title_sort | impact of body mass on p2y12-inhibitor de-escalation in acute coronary syndromes—a substudy of the tropical-acs trial |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627813/ https://www.ncbi.nlm.nih.gov/pubmed/37015874 http://dx.doi.org/10.1093/ehjcvp/pvad027 |
work_keys_str_mv | AT komocsiandras impactofbodymassonp2y12inhibitordeescalationinacutecoronarysyndromesasubstudyofthetropicalacstrial AT merkelybela impactofbodymassonp2y12inhibitordeescalationinacutecoronarysyndromesasubstudyofthetropicalacstrial AT hadamitzkymartin impactofbodymassonp2y12inhibitordeescalationinacutecoronarysyndromesasubstudyofthetropicalacstrial AT massbergsteffen impactofbodymassonp2y12inhibitordeescalationinacutecoronarysyndromesasubstudyofthetropicalacstrial AT rizaskonstantinosd impactofbodymassonp2y12inhibitordeescalationinacutecoronarysyndromesasubstudyofthetropicalacstrial AT heinrothweilerralph impactofbodymassonp2y12inhibitordeescalationinacutecoronarysyndromesasubstudyofthetropicalacstrial AT grosslisa impactofbodymassonp2y12inhibitordeescalationinacutecoronarysyndromesasubstudyofthetropicalacstrial AT trenkdietmar impactofbodymassonp2y12inhibitordeescalationinacutecoronarysyndromesasubstudyofthetropicalacstrial AT sibbingdirk impactofbodymassonp2y12inhibitordeescalationinacutecoronarysyndromesasubstudyofthetropicalacstrial AT aradidaniel impactofbodymassonp2y12inhibitordeescalationinacutecoronarysyndromesasubstudyofthetropicalacstrial |